SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
A phase 2 trial of SSGJ-705 and SSGJ-612 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
Overview
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors is a phase 2 interventional study registered as NCT07646626 by Shenyang Sunshine Pharmaceutical Co., LTD., with 150 participants planned, started 2026-07-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: SSGJ-705, SSGJ-612 and SSGJ-705 combined with chemotherapy.
Similar pages
not linked directly; found by shared links- TrialSSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Shares SSGJ-705, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.